We selected several factors—age, haemoglobin, estimated glomerular filtration rate (eGFR), type of cancer therapy, cardioprotective drugs, cancer stage, and HFA-ICOS cardiotoxicity risk—to examine their impact on the hs-cTnT deviation as a longitudinal variable. This evidence concerns the gene TNNT2 and cancer.